Editor’s note: This is not an exhaustive list. Deals are listed in chronological order from most to least recent.
- McKesson signed a deal with the U.S. to be a central distributor of a COVID-19 vaccine and the supplies needed to administer it.
- Moderna signed a deal with the U.S. valued at up to $1.5 billion for 100 million doses of its COVID-19 vaccine candidate.
- Johnson & Johnson signed a more than $1 billion deal with the U.S. for 100 million doses of its investigational COVID-19 vaccine.
- The U.S. signed a deal with Sanofi and GlaxoSmithKline to pay the drugmakers up to $2.1 billion for the development and supply of a COVID-19 vaccine they are partnering on.
- Pfizer and BioNTech signed a $1.9 billion deal with the U.S. to secure up to 600 million doses of BNT162, the two drugmakers’ jointly-developed COVID-19 vaccine candidate.
- Novavax signed a $1.6 billion deal with the U.S. to expedite development of its COVID-19 vaccine.
- Emergent BioSolutions signed a $628 million deal with the U.S. to ramp up its contract development and manufacturing capabilities to expedite the delivery of COVID-19 vaccines.
- AstraZeneca signed a more than $1 billion deal with the U.S. to support increased access to its COVID-19 vaccine.
More articles on pharmacy:
FDA extends remdesivir’s emergency use authorization to all hospitalized COVID-19 patients
Walgreens names former Rite Aid CEO as its new president
Heads roll at FDA after commissioner’s comments on convalescent plasma
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
